Understanding US addiction physicians' low rate of naltrexone prescription

Drug and Alcohol Dependence

Volumn 71, Issue 3, 2003, Pages 219-228

  Mark, Tami L ^a   Kranzler, Henry R ^b   Song, Xue ^c  

^a MEDSTAT GROUP   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c MEDSTAT Group   (United States)

Author keywords

Alcohol dependence; Alcoholism treatment; Naltrexone; Prescribing patterns

Indexed keywords

NALTREXONE;

ALCOHOLISM; CLINICAL PRACTICE; COGNITIVE DEFECT; DEPRESSION; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; DYSPHORIA; GASTROINTESTINAL DISEASE; HEADACHE; HEALTH SURVEY; HUMAN; LIVER DISEASE; LOGISTIC REGRESSION ANALYSIS; MEDICAL LITERATURE; MULTIVARIATE ANALYSIS; PATIENT ATTITUDE; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SELF REPORT; SIDE EFFECT; UNITED STATES; ADDICTION; ARTICLE; ECONOMICS; INFORMATION PROCESSING; PATIENT COMPLIANCE; PHYSICIAN; STATISTICAL MODEL; STATISTICS;

DATA COLLECTION; HUMANS; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; NALTREXONE; PATIENT COMPLIANCE; PHYSICIANS; PRESCRIPTIONS, DRUG; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 1542264857     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(03)00134-0     Document Type: Article

References (46)

1. Armstrong D., Reyburn H., Jones R. A study of general practitioner's reason for changing their prescribing behavior. British Medical Journal. 312:1996;94-952.
2. Berndt, E.R., Pindyck, R.S., Azoulay, P., 1999. Network effects and diffusion in pharmaceutical markets: anti-ulcer drugs. National Bureau of Economic Research working paper series.
3. Chren M.M., Landefeld C.S. Physician's behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. Journal of American Medical Association. 271:1994;684-689.
4. Coleman J., Katz E., Menzel H. Medical Innovations - A Diffusion Study. 1966;Bobbs-Merrill, New York.
5. Davis P., Gribben B. Rational prescribing and interpractitioner variation. International Journal of Technology Assessment in Health Care. 11:1995;428-443.
6. Denig P., Haaijer-Ruskamp F., Zusling D. How physicians choose drugs. Social Science and Medicine. 27:1988;1381-1386.
7. Epstein A.M., Leighton R.J., Winickoff R. Physician beliefs, attitudes, and prescribing behavior for antiinflammatory drugs. American Journal of Medicine. 77:1984;313-318.
8. Fuhrer M.J., Grabois M.G. Information sources that influence physiatrists' adoption of new clinical practices. Archives of Physical Medicine and Rehabilitation. 69:1988;167-169.
9. Garbutt J.C., West S.L., Carey T.S., Lohr K.N., Crews F.T. Pharmacological treatment of alcohol dependence: a review of the evidence. Journal of American Medical Association. 281:(14):1999;1318-1325.
10. Graham R., Wodak A.D., Whelan G. New pharmacotherapies for alcohol dependence. Medical Journal of Australia. 177:2002;103-107.
11. Heinala P., Alho H., Kiianmaa K., Lonnqvist J., Kuoppasalmi K., Sinclair J.D. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology. 21:(3):2001;287-292.
12. Health I.M.S., National Prescription Audit Plus T.M. Data provided from audits of US Prescription Drug Store Sales. 2001;IMS Health, Fairfield, CT.
13. IMS Health. IMS MIDAS 3Q02. 2002;IMS Health, Fairfield, CT.
14. Jaffe A.J., Rounsaville B., Chang G., Schottenfeld R.S., Meyer R.E., O'Malley S.S. Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. Journal of Consulting and Clinical Psychology. 64:1996;1044-1053.
15. Kranzler H.R., Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcoholism: Clinical and Experimental Research. 25:2001;1335-1341.
16. Krystal J.H., Cramer J.A., Krol W.F., Kirk G.F., Rosenheck R.A. Naltrexone in the treatment of alcohol dependence. New England Journal of Medicine. 345:2001;1734-1739.
17. Lipsey M.W. Design Sensitivity: Statistical Power for Experimental Research. 1990;Sage Publications, Newbury Park, CA.
18. Mark, T.L., Kranzler, H.R., Poole, V.H., Hagen, C.A, McLeod, C., Crosse, S., Barriers to the use of medications to treat alcoholism, The American Journal on Addictions, in press.
19. Mark, T.L, Swait, J., 2003. Using stated preference modeling to forecast the effect of medication attributes on prescription of alcoholism medications. Value Health Jul-Aug 6 (4), 474-482.
20. Markson L.E., Cosler L.E., Turner B. Implications of generalist's slow adoption of zidovudine in clinical practice. Archives of Internal Medicine. 154:1994;1497-1503.
21. Monterosso J.R., Flannery B.A., Pettinati H.M., Oslin D.W., Rukstalis M., O'Brien C.P., Volpicelli J.R. Predicting treatment response to naltrexone: the influence of craving and family history. The American Journal on Addictions. 10:2001;258-268.
22. Monti P.M., Rohsenow D.J., Swift R.M., Gulliver S.B., Colby S.M., Mueller T.I., Brown R.A., Gordon A., Abrams D.B., Niaura R.S., Asher M.K. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes, alcoholism. Clinical and Experimental Research. 25:(11):2001;1634-1647.
23. Morris L.P., Hopwood M., Whelan G., Gardiner J., Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction. 96:(11):2001;1564-1573.
24. Mosby's GenRX, 1998. eighth ed., Mosby-Year Book, Inc., St. Louis, MO.
25. O'Malley S.S., Jaffe A., Chang G., Schottenfeld R.S., Meyer R.E., Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Archives of General Psychiatry. 49:1992;881-887.
26. Peay M.Y., Peay E.R. The role of commercial sources in the adoption of a new drug. Social Science and Medicine. 26:1988;1183-1189.
27. Peay M., Peay E. Patterns of preference for information sources in the adoption of new drugs by specialists. Social Science and Medicine. 31:(4):1990;467-476.
28. Pettinati H.M., Volpicelli J.R., Pierce J.D., O'Brien C.P. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. Journal of Addictive Diseases. 19:(1):2000;71-83.
29. Rohsenow D.J., Colby S.M., Monti P.M., Swift R.M., Martin R.A., Mueller R.I., Gordon A., Eaton C.A. Predictors of compliance with naltrexone among alcoholics. Alcoholism: Clinical and Experimental Research. 24:(1):2000;1542- 1549.
30. Roman P.M., Johnson J.A. Adoption and implementation of new technologies in substance abuse treatment. Journal of Substance Abuse Treatment. 22:2002;211-218.
31. Rosenberg H., Melville J., McLean P.C. Acceptability and availability of pharmaceutical interventions for substance misuse by British NHS treatment servcies. Addiction. 97:2002;59-65.
32. Rubin D.B. Inference and missing data. Biometrika. 63:1976;581-592.
33. Rubin D.B. Multiple Mputation for Nonresponse in Surveys. 1987;Wiley, New York.
34. Saitz R., O'Malley S.S. Pharmacotherapies for alcohol abuse. Withdrawal and treatment. The Medical Clinics of North America. 81:(4):1997;881-907.
35. Substance Abuse and Mental Health Agency (SAMHSA). National household survey on drug abuse, http://www.samhsa.gov/oas/Dependence/appendixf.htm, downloaded, February 2003.
36. SAS OnlineDoc: Version 8. http://www.sas.com/rnd/app/papers/miv802.pdf.
37. Segal R., Hepler C. Prescribers' beliefs and values as predictors of drug choices. American Journal of Hospital Pharmacists. 39:1982;1891-1897.
38. Streeton C., Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol and Alcoholism. 36:(6):2001;544-552.
39. Strickland-Hodge B., Jepson M. Identification and characterization of early and late prescribers in general practice. Journal of the Royal Society of Medicine. 75:1982;341-345.
40. Stross J. Information sources and clinical decisions. Journal of General Internal Medicine. 2:(3):1987;155-159.
41. Swift R.M., Duncan D., Nirenberg T., Femino J. Alcoholic patients' experience and attitudes on pharmacotherapy for alcoholism. Journal of Addictive Diseases. 17:(3):1998;35-47.
42. Volpicelli J.R., Alterman A.I., Hayashida M., O'Brien C.P. Naltrexone in the treatment of alchohol dependence. Archives of General Psychiatry. 49:1992;876-880.
43. Volpicelli J.R., Clay K.L., Watson N.T., O'Brien C.P. Naltrexone in the treatment of alcoholism: predicting response to naltrexone. Journal of Clinical Psychiatry. 56:1995;39-44.
44. Wazana A. Physicians and the pharmaceutical industry. Is a gift ever just a gift. Journal of American Medical Association. 283:(3):2000;373-380.
45. Wetterling T., Veltrup C., Junghanns K., Kromer-Olbrisch T., Schneider U. Acceptance of pharmacotherapy for relapse prevention by chronic alcoholics. Pharmacopsychiatry. 34:(4):2002;142-146.
46. Zelnio R. The interaction among the criteria physicians use when prescribing. Medical Care. 20:(3):1982;277-285.